EA200601660A1 - MTP INHIBITING ARYLIPIPERIDINES OR PIPERASINES FURNISHED WITH 5-MEMBER HETEROCYCLES - Google Patents

MTP INHIBITING ARYLIPIPERIDINES OR PIPERASINES FURNISHED WITH 5-MEMBER HETEROCYCLES

Info

Publication number
EA200601660A1
EA200601660A1 EA200601660A EA200601660A EA200601660A1 EA 200601660 A1 EA200601660 A1 EA 200601660A1 EA 200601660 A EA200601660 A EA 200601660A EA 200601660 A EA200601660 A EA 200601660A EA 200601660 A1 EA200601660 A1 EA 200601660A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
diabetes
relates
piperasines
arylipiperidines
Prior art date
Application number
EA200601660A
Other languages
Russian (ru)
Other versions
EA009455B1 (en
Inventor
Ливен Мерпул
Лео Якобус Йозеф Бакс
Либуше Яроскова
Петер Вальтер Мария Рувенс
Луи Йозеф Элизабет Ван Дер Векен
Марсель Вьейевуа
Йоаннес Теодорус Мария Линдерс
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200601660A1 publication Critical patent/EA200601660A1/en
Publication of EA009455B1 publication Critical patent/EA009455B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Настоящее изобретение относится к новым арилпиперидиновым или пиперазиновым производным, замещенным определенными 5-членными гетероциклами, обладающим ингибирующей активностью в отношении секреции апоВ/МТР и сопутствующей активностью в отношении снижения уровня липидов. Кроме того, изобретение относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения, а также применению указанных соединений в качестве лекарственного средства для лечения гиперлипидемии, ожирения и диабета типа II (формула (I)). Также изобретение относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения, а также применению указанных соединений в качестве лекарственного средства для лечения атеросклероза, панкреатита, ожирения, гипертриглицеридемии, гиперхолестеринемии, гиперлипидемии, диабета или диабета типа II.The present invention relates to a novel arylpiperidine or piperazine derivative substituted with certain 5 membered heterocycles having inhibitory activity against apoB / MTP secretion and concomitant activity towards lowering lipid levels. In addition, the invention relates to methods for producing such compounds, pharmaceutical compositions containing these compounds, as well as the use of these compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (formula (I)). The invention also relates to methods for producing such compounds, pharmaceutical compositions containing these compounds, as well as the use of these compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes or type II diabetes.

EA200601660A 2004-03-10 2005-03-07 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles EA009455B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04075771 2004-03-10
PCT/EP2005/051010 WO2005085226A1 (en) 2004-03-10 2005-03-07 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles

Publications (2)

Publication Number Publication Date
EA200601660A1 true EA200601660A1 (en) 2006-12-29
EA009455B1 EA009455B1 (en) 2007-12-28

Family

ID=34928108

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601660A EA009455B1 (en) 2004-03-10 2005-03-07 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles

Country Status (27)

Country Link
US (2) US7504400B2 (en)
EP (1) EP1751131B1 (en)
JP (1) JP4846709B2 (en)
KR (1) KR101171211B1 (en)
CN (1) CN1930143B (en)
AR (1) AR048316A1 (en)
AT (1) ATE414698T1 (en)
AU (1) AU2005219580B2 (en)
BR (1) BRPI0508514A (en)
CA (1) CA2558506C (en)
DK (1) DK1751131T3 (en)
EA (1) EA009455B1 (en)
ES (1) ES2317206T3 (en)
HK (1) HK1103582A1 (en)
IL (1) IL177939A (en)
JO (1) JO2537B1 (en)
MX (1) MXPA06010253A (en)
MY (1) MY142521A (en)
NZ (1) NZ548817A (en)
PA (1) PA8625401A1 (en)
PL (1) PL1751131T3 (en)
PT (1) PT1751131E (en)
SI (1) SI1751131T1 (en)
TW (1) TWI353984B (en)
UA (1) UA85215C2 (en)
WO (1) WO2005085226A1 (en)
ZA (1) ZA200607542B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP1948629A1 (en) * 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
ES2382009T3 (en) * 2006-12-01 2012-06-04 Bristol-Myers Squibb Company N - ((3-Benzyl) -2,2- (bis-phenyl -) - propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
WO2009079593A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
CN102083839B (en) 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 Compounds
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
RU2585760C2 (en) * 2010-05-19 2016-06-10 Сандоз Аг Method of producing chiral triazolones
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6240667B2 (en) * 2012-05-22 2017-11-29 アウトイフオンイ トヘラペウトイクス リミテッド Triazoles as KV3 inhibitors
WO2014164767A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
WO2014175621A1 (en) * 2013-04-25 2014-10-30 Yuhan Corporation Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same
JP2016526538A (en) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Aryl sulfide and aryl sulfoxide derivatives as acaricides and insecticides
EP3010893B1 (en) 2013-06-20 2019-10-02 Bayer CropScience Aktiengesellschaft Arylsulfide and arylsulfoxide derivatives as acaricides and insecticides
US9771351B2 (en) 2013-07-29 2017-09-26 Kyowa Hakko Kirin Co., Ltd. Wnt signaling inhibitor
WO2015200674A1 (en) * 2014-06-25 2015-12-30 The General Hospital Corporation Neuroactive compounds and methods of using the same
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
KR102457933B1 (en) * 2016-05-27 2022-10-24 브리스톨-마이어스 스큅 컴퍼니 Triazolones and Tetrazolones as Inhibitors of ROCK
EP3484877B1 (en) 2016-07-12 2020-07-01 Bayer CropScience Aktiengesellschaft Bicyclic compounds as pest controllers
CN110198942B (en) 2017-01-24 2022-04-15 住友化学株式会社 Fused heterocyclic compound and composition containing the same
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2022187206A1 (en) * 2021-03-01 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof
GB202216960D0 (en) * 2022-11-14 2022-12-28 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents

Also Published As

Publication number Publication date
CA2558506C (en) 2012-09-11
EA009455B1 (en) 2007-12-28
BRPI0508514A (en) 2007-08-14
US7816360B2 (en) 2010-10-19
IL177939A (en) 2011-08-31
TWI353984B (en) 2011-12-11
US20100004263A1 (en) 2010-01-07
AU2005219580B2 (en) 2010-07-08
JO2537B1 (en) 2010-09-05
KR101171211B1 (en) 2012-08-07
DK1751131T3 (en) 2009-03-16
ES2317206T3 (en) 2009-04-16
SI1751131T1 (en) 2009-04-30
KR20070014121A (en) 2007-01-31
AR048316A1 (en) 2006-04-19
US7504400B2 (en) 2009-03-17
UA85215C2 (en) 2009-01-12
HK1103582A1 (en) 2007-12-21
MY142521A (en) 2010-12-15
JP4846709B2 (en) 2011-12-28
WO2005085226A1 (en) 2005-09-15
PA8625401A1 (en) 2005-09-28
AU2005219580A1 (en) 2005-09-15
CN1930143B (en) 2012-04-04
IL177939A0 (en) 2006-12-31
EP1751131B1 (en) 2008-11-19
CA2558506A1 (en) 2005-09-15
CN1930143A (en) 2007-03-14
NZ548817A (en) 2009-04-30
TW200540169A (en) 2005-12-16
US20070191383A1 (en) 2007-08-16
MXPA06010253A (en) 2007-02-16
PL1751131T3 (en) 2009-04-30
EP1751131A1 (en) 2007-02-14
PT1751131E (en) 2009-02-13
JP2007527897A (en) 2007-10-04
ZA200607542B (en) 2008-05-28
ATE414698T1 (en) 2008-12-15

Similar Documents

Publication Publication Date Title
EA200601660A1 (en) MTP INHIBITING ARYLIPIPERIDINES OR PIPERASINES FURNISHED WITH 5-MEMBER HETEROCYCLES
EA200970398A1 (en) DERIVATIVES OF PIPERIDINE OR PIPERAZIN SUBSTITUTED TETRAHYDRO-NAPTHALINE 1-CARBONIC ACID INHIBITING MTR
HRP20050103B1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
DE60315336D1 (en) PHARMACEUTICAL COMPOSITION AND ITS USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV (DPP-IV)
EA200601239A1 (en) REPLACED QUINOLINE COMPOUNDS
BRPI0410630A (en) nk1 antagonist
EA200870521A1 (en) SUBSTITUTED SPIROCYCLIC ANTAGONISTS OF CGRP RECEPTORS
EA200900023A1 (en) USE OF SUBSTITUTED 2-AMINOTHETRALINES FOR THE PRODUCTION OF MEDICINES FOR THE PREVENTION, FACILITATION AND / OR TREATMENT OF DIFFERENT KINDS OF PAIN
ATE524181T1 (en) USE OF 1,4-BIS(3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
DE502004006619D1 (en) SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTIVE TREATMENT OF MORBUS PARKINSON
DE602004008959D1 (en) BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE
ATE412636T1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AN AGAINST OBESITY
NO20060718L (en) Substituted thiophones and their use
EA200870223A1 (en) DERIVATIVES OF BENZOIZOINDOL FOR THE TREATMENT OF PAIN
HK1137011A1 (en) Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
EA200801137A1 (en) COMPOUNDS FOR INHIBITING APOPTOSIS
ATE308513T1 (en) NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICATIONS
EA200400409A1 (en) NEW IZOHINOLIN COMPOUNDS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO20064601L (en) Mtp-inhibiting aryl-piperidines or -piperazines substituted with 5-membered heterocycles
DE60305727D1 (en) HYPOESTOXIDES, DERIVATIVES AND AGONISTS THEREOF FOR USE IN THE TREATMENT AND PROPHYLAXIS OF HYPERLIPIDEMIA
JO2529B1 (en) N-aryl piperidine substituted biphenylcarboxamides

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU